Discontinued — last reported Q1 '26
Dificid — Sales
Merck & Co. Dificid — Sales decreased by 32.0% to $34.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 79.5%, from $166.00M to $34.00M. Over 4 years (FY 2021 to FY 2025), Dificid — Sales shows an upward trend with a 8.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful clinical utilization, while a decrease may signal increased competition, patent expiration, or a shift in treatment guidelines.
Detailed definition
This metric represents the total annual net revenue generated from the sale of a specific pharmaceutical product line fo...
Peer comparison
Comparable to revenue metrics for specific branded pharmaceutical products or niche therapeutic franchises at other large-cap biopharmaceutical companies.
mrk_segment_dificid_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $68.00M | $108.00M | $121.00M | $104.00M | $132.00M | $155.00M | $135.00M | $130.00M | $152.00M | $148.00M | $174.00M | $146.00M | $183.00M | $192.00M | $159.00M | $166.00M | $192.00M | $86.00M | $50.00M | $34.00M |
| QoQ Change | — | +58.8% | +12.0% | -14.0% | +26.9% | +17.4% | -12.9% | -3.7% | +16.9% | -2.6% | +17.6% | -16.1% | +25.3% | +4.9% | -17.2% | +4.4% | +15.7% | -55.2% | -41.9% | -32.0% |
| YoY Change | — | — | — | — | +94.1% | +43.5% | +11.6% | +25.0% | +15.2% | -4.5% | +28.9% | +12.3% | +20.4% | +29.7% | -8.6% | +13.7% | +4.9% | -55.2% | -68.6% | -79.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s dificid — sales?
- Merck & Co. (MRK) reported dificid — sales of $34.00M in Q1 2026.
- How has Merck & Co.'s dificid — sales changed year-over-year?
- Merck & Co.'s dificid — sales decreased by 79.5% year-over-year, from $166.00M to $34.00M.
- What is the long-term trend for Merck & Co.'s dificid — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s dificid — sales has grown at a 8.9% compound annual growth rate (CAGR), from $351.00M to $494.00M.
- What does dificid — sales mean?
- The total annual revenue generated from the sales of a specific antibiotic product.